Qiming Venture Partners

🔊 Looking back, what Qiming Venture Partners has achieved? Find out more in 60 seconds.

Check out WeRide's commercial deployment of its Robosweeper S1 in Shantou, Guangdong, marking the city's first L4-level autonomous sanitation project on public roads and the debut of the WeRide Robosweeper S1 in the eastern Guangdong region. The Robosweeper S1 began safety testing in June in Shantou. Upon completion of the trial period, it will commence continuous autonomous sanitation operations along Haibin Road, providing reliable day-and-night service. WeRide's smart sanitation solutions are already making an impact in multiple cities, enhancing urban environments with exceptional efficiency and quality. This not only drives the intelligent upgrade of traditional sanitation services but also highlights the adaptability of WeRide's products in various settings, reinforcing the scalability of the company's business model. #AutonomousDriving #SmartCity #Robotics #UrbanSanitation #Innovation #L4Autonomy #QimingPortfolio #QimingTechnology

Our portfolio company ZHUHAI DL Biotech CO., Ltd. (NEEQ: 873831) announced the successful installation of the DL-96A Fully Auto Microbial ID/AST System and Smart MS 5020 Auto Microbial Rapid Identification Mass Spectrometer System in Latin America and the Middle East. This milestone highlights DL Biotech's commitment to supporting mega labs and large hospitals in handling high volumes of samples. The DL-96A is a fully automated microbial ID/AST system with an integrated incubator and dispensing. The Smart MS 5020 is a rapid, accurate, and high-throughput microbial identification system utilizing MALDI-TOF MS technology for species-level identification in just a few seconds. #Biotech #MedicalTechnology #Microbiology #Diagnostics #GlobalHealthcare #Innovation #QimingPortfolio #QimingHealthcare

Aohua Endoscopy Co., Ltd. (SHSE: 688212) has introduced its latest lineup of innovative products, including: - Hyperspectral Imaging Platform: Featuring 26 spectral bands, this platform provides detailed, multi-layered optical feedback. It intelligently captures subtle differences and optimizes real-time imaging for precise and detailed visuals. - AQ-150 Series 4K UHD Endoscopy System: Offers exceptional image clarity for accurate clinical diagnostics. Its user-friendly flip-cover touchscreen design enhances control and streamlines the operational process. - AQ-120 Series Endoscopy System: Combines a touch panel with a compact main unit for superior ease of use. Its advanced image processor significantly enhances detail resolution and is adaptable across various medical specialties, improving diagnostic capabilities in both primary and specialized care settings. The advancements are set to contribute to more equitable access to high-quality medical care. #Endoscopy #MedicalTechnology #Innovation #Healthcare #Diagnostics #QimingPortfolio #QimingHealthcare

Hesai Technology (NASDAQ: HSAI) has equipped the new WEY Lanshan six-seat smart flagship SUV with its ultra-high resolution long-range lidar, the AT128. This innovative SUV features 27 smart sensors, including the AT128, enhancing its ability to provide precise and comprehensive driving assistance with 30 advanced L2+ features, such as highway and city NOA, memory parking, and remote parking. This integration not only enhances driving convenience but also sets a new standard for safety and intelligent driving. The AT128 stands out with its 128 VCSELs, delivering an impressive 1200×128 resolution and a point rate of 1.53 million per second. With a 200-meter range, it captures detailed object information, addressing the challenges of high-precision perception without relying on high-definition maps. #Lidar #SmartDriving #AutomotiveInnovation #VehicleSafety #Innovation #QimingPortfolio #QimingTechnology

In an insightful conversation with PharmaBoardroom, our Managing Partner, Nisa Leung, shared some of our key achievements, including the successful completion of two funds over the past two years, 41 IPOs since 2020, and our engagement in M&A activities this year. Nisa also discussed the evolving landscape of BD deals in healthcare, particularly the growing trend of licensing innovative drugs from China to global markets. This trend is driven by the ability of Chinese companies to develop innovative, best-in-class, cost-effective drugs with quick turnarounds. Currently, Qiming Venture Partners has over 300 drug assets in its portfolio, with more than 120 in clinical development worldwide—numbers that continue to grow. She introduced the evolution of the healthcare talent pool, noting that China produces around 5 million STEM graduates each year, fueling the next generation of biotech entrepreneurs. Nisa encouraged these talents to think globally, cross-pollinate ideas, and collaborate. She also highlighted the shift in BD models, with innovative companies engaging international investors early and conducting multi-regional clinical trials to accelerate global outreach. Establishing manufacturing and R&D centers worldwide, she noted, allows companies to collaborate with local talents and key opinion leaders, further driving growth and innovation. For more of Nisa's insights, check out the interview below: https://lnkd.in/gg6qR9j7 #Biotech #Innovation #VentureCapital #GlobalMarkets #PharmaBoardroom #IPO #LicensingDeals #STEM #Entrepreneurship #QimingInsights

Our portfolio company, Photon Crystal Energy, has successfully launched its 100MW perovskite pilot production line and rolled out its first product in Foshan, Guangdong. This achievement represents a major milestone in advancing the large-scale industrial production and commercialization of perovskite solar cells, which lays a solid foundation for expanding to GW-level production lines. Known for their wide availability of materials, efficient manufacturing process, lower costs, and high conversion efficiency, perovskite solar cells show great potential as a viable alternative to traditional crystalline silicon solar cells. Photon Crystal Energy has also signed strategic cooperation agreements with key customers and partners. Together, they will explore new opportunities in distributed solar photovoltaics, building-integrated photovoltaics (BIPV), colored PV products, and international markets, advancing the innovation and commercialization of perovskite PV products. Photon Crystal Energy has secured over 100 million RMB in Series A+ funding, with Qiming Venture Partners making a super pro-rata investment. This funding will provide the impetus needed to overcome engineering challenges, enhance production capacity and yield, and prepare for GW-level mass production. #Perovskite #SolarEnergy #RenewableEnergy #Photovoltaics #BIPV #Innovation #Sustainability #CleanEnergy #QimingPortfolio #QimingTechnology

Pluslife's self-developed Tuberculosis (TB) rapid molecular diagnostic kit for tongue swab samples has been granted an import license by the Indonesian government. This milestone follows the successful certification of the company's sputum sample diagnostic technology and represents a significant breakthrough in TB detection. The WHO's Global Tuberculosis Report 2023 recommends rapid molecular diagnostics as the preferred method for initial TB screening due to its high sensitivity and specificity. This tool is crucial for early detection and reducing waiting times for results. However, the global shortage of affordable and decentralized TB rapid molecular diagnostics has hindered progress, especially in resource-limited primary care settings and high-burden regions. To address this gap, Pluslife has developed a dual-sample TB rapid molecular diagnostic product that combines high performance with low cost and ease of use. This solution is designed to meet the needs of decentralized testing, enabling efficient operation in primary care settings with limited resources. #Tuberculosis #MolecularDiagnostics #GlobalHealth #Innovation #DecentralizedTesting #PublicHealth #MedicalTechnology #ESG #QimingPortfolio #QimingHealthcare

Abogen Biosciences has published a paper in Nucleic Acids Research, introducing its proprietary cis-splicing system, a high-efficiency RNA circularization technology that produces circular RNA (circRNA) with prolonged protein expression, minimal activation of the innate immune response, and flexible splice site design—paving the way for promising new applications. The PCT patent for the circRNA from cis-splicing system is currently under public review. This system shows potential for developing and industrializing circRNA therapeutics. The cis-splicing system incorporates a ribozyme core at one end of the precursor RNA, eliminating the need for additional spacer elements between the ribozyme and the gene of interest (GOI), thereby streamlining the circularization process and improving efficiency—a key advancement in the synthesis of high-quality circRNA. #RNAInnovation #circRNA #BiotechResearch #NucleicAcidsResearch #CisSplicing #GeneticEngineering #RNAtherapeutics #Biopharma #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gkhiMg97

QuantaSing (NASDAQ: QSG) announced the launch of its new mission and vision statements, marking the beginning of a transformative journey. With the mission "Live better, live longer," QuantaSing reaffirms its dedication to enhancing the quality of life for adults across various life stages. The vision to "Become a long-term partner loved and trusted by adult users" further underscores the company’s commitment to addressing the multifaceted needs of adults in their middle and later years. #MissionAndVision #BusinessTransformation #QualityOfLife #SeniorWellbeing #LongTermPartnership #AdultCare #MiddleAgedCare #QimingPortfolio